NCT05289687 2026-03-02Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALLEastern Cooperative Oncology GroupPhase 2 Recruiting20 enrolled
NCT04139304 2025-06-29A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic LymphomaAIDS Malignancy ConsortiumPhase EARLY_PHASE1 Recruiting15 enrolled